News


All series


All News

The combination of encorafenib, binimetinib, and cetuximab reduced the risk of death by 48% in patients wtih&nbsp;<em>BRAF</em> V600E-mutant metastatic colorectal cancer who have received up to 2 prior lines of therapy compared with cetuximab and irinotecan-containing regimens, according to the phase III BEACON CRC trial, which met both its primary endpoints.